Vaxart Statistics
Total Valuation
Vaxart has a market cap or net worth of $92.52 million. The enterprise value is $64.34 million.
Important Dates
The next confirmed earnings date is Tuesday, May 13, 2025, after market close.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxart has 227.95 million shares outstanding. The number of shares has increased by 39.58% in one year.
| Current Share Class | 227.95M |
| Shares Outstanding | 227.95M |
| Shares Change (YoY) | +39.58% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 0.79% |
| Owned by Institutions (%) | 13.02% |
| Float | 226.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.87 |
| Forward PS | 1.72 |
| PB Ratio | 1.57 |
| P/TBV Ratio | 1.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.75, with a Debt / Equity ratio of 0.40.
| Current Ratio | 0.75 |
| Quick Ratio | 0.70 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -22.33 |
Financial Efficiency
Return on equity (ROE) is -114.71% and return on invested capital (ROIC) is -49.76%.
| Return on Equity (ROE) | -114.71% |
| Return on Assets (ROA) | -32.09% |
| Return on Invested Capital (ROIC) | -49.76% |
| Return on Capital Employed (ROCE) | -87.79% |
| Revenue Per Employee | $273,333 |
| Profits Per Employee | -$637,600 |
| Employee Count | 105 |
| Asset Turnover | 0.22 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Vaxart has paid $260,000 in taxes.
| Income Tax | 260,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.88% in the last 52 weeks. The beta is 1.28, so Vaxart's price volatility has been higher than the market average.
| Beta (5Y) | 1.28 |
| 52-Week Price Change | -44.88% |
| 50-Day Moving Average | 0.43 |
| 200-Day Moving Average | 0.66 |
| Relative Strength Index (RSI) | 50.24 |
| Average Volume (20 Days) | 1,452,456 |
Short Selling Information
The latest short interest is 13.16 million, so 5.77% of the outstanding shares have been sold short.
| Short Interest | 13.16M |
| Short Previous Month | 12.92M |
| Short % of Shares Out | 5.77% |
| Short % of Float | 5.82% |
| Short Ratio (days to cover) | 6.61 |
Income Statement
In the last 12 months, Vaxart had revenue of $28.70 million and -$66.95 million in losses. Loss per share was -$0.33.
| Revenue | 28.70M |
| Gross Profit | -45.51M |
| Operating Income | -66.29M |
| Pretax Income | -75.38M |
| Net Income | -66.95M |
| EBITDA | -57.44M |
| EBIT | -66.29M |
| Loss Per Share | -$0.33 |
Full Income StatementBalance Sheet
The company has $51.72 million in cash and $23.28 million in debt, giving a net cash position of $28.44 million or $0.12 per share.
| Cash & Cash Equivalents | 51.72M |
| Total Debt | 23.28M |
| Net Cash | 28.44M |
| Net Cash Per Share | $0.12 |
| Equity (Book Value) | 58.93M |
| Book Value Per Share | 0.26 |
| Working Capital | -22.62M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$44.76 million and capital expenditures -$554,000, giving a free cash flow of -$45.32 million.
| Operating Cash Flow | -44.76M |
| Capital Expenditures | -554,000 |
| Free Cash Flow | -45.32M |
| FCF Per Share | -$0.20 |
Full Cash Flow StatementMargins
Gross margin is -158.58%, with operating and profit margins of -230.99% and -233.27%.
| Gross Margin | -158.58% |
| Operating Margin | -230.99% |
| Pretax Margin | -232.36% |
| Profit Margin | -233.27% |
| EBITDA Margin | -200.15% |
| EBIT Margin | -230.99% |
| FCF Margin | n/a |
Dividends & Yields
Vaxart does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -39.58% |
| Shareholder Yield | -39.58% |
| Earnings Yield | -72.16% |
| FCF Yield | -48.85% |
Dividend DetailsAnalyst Forecast
The average price target for Vaxart is $3.00, which is 639.10% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 639.10% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 44.39% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Vaxart has an Altman Z-Score of -4.4 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.4 |
| Piotroski F-Score | 4 |